Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Immunochromatographic test for rapid simultaneous detection of prostate-specific-antigen and α-amylase.

Created on 02 Sep 2026

Authors

Christophe Frippiat, Tom Heylen, Océane Albano, Vanessa Vanvooren

Published in

Science & justice : journal of the Forensic Science Society. Volume 66. Issue 5. Pages 101497. Epub Aug 05, 2026.

Abstract

The detection of biological fluids such as semen and saliva is crucial in forensic investigations. However, no existing immunochromatographic test allows the simultaneous detection of these two body fluids, which means that if a sample is suspected to contain a mixture of these, multiple tests must be performed, thereby consuming the biological trace. To address this gap, SERATEC® has developed a new rapid test, the SERATEC® PAM test, capable of simultaneously detecting Prostate-Specific Antigen and α-amylase. This study aimed to validate this new commercial test. Our data show that this test is a valuable tool for forensic investigations. Nevertheless, the occurrence of false-positive results with other biological fluids indicates that this immunochromatographic test should only be used for the presumptive identification of biological fluids and cannot definitively determine their nature. A cautious interpretation of the results in the context of investigations is therefore necessary.

PMID:
42680470
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement